BACKGROUND: Recent concerns have emerged on the potential higher risk of stent thrombosis after DES implantation, that might be even more pronounced among STEMI patients. The aim of the current study was to perform a meta-analysis to evaluate the benefits and safety of Sirolimus-Eluting Stent (SES) as compared to BMS in patients undergoing primary angioplasty for STEMI. METHODS: The literature was scanned by formal searches of electronic databases (MEDLINE and CENTRAL). We examined all completed randomized trials of DES for STEMI. The following keywords were used for study selection: randomized trial, myocardial infarction, reperfusion, primary angioplasty, stenting, DES, sirolimus-eluting stent (SES), Cypher. Information on study design, type of stent, inclusion and exclusion criteria, primary endpoint, number of patients, angiographic and clinical outcome, were extracted by two investigators. Disagreements were resolved by consensus. RESULTS: A total of 9 trials were included in the meta-analysis, involving 2,769 patients (1389 or 50.2% randomized to DES and 1,380 or 49.8% randomized to BMS). At 12 months follow-up, SES was associated with a significant reduction in TVR (4.9% vs. 13.6%, p < 0.0001), with a trend in benefits in mortality (2.9% vs. 4.2%, p = 0.08) and reinfarction (3.0% vs. 4.3%, p = 0.06), without any significant difference in stent thrombosis (1.9% vs. 2.5%, p = 0.36). Safety and efficacy of DES were confirmed at 2-3 years follow-up (data available from 4 trials including 569 patients). CONCLUSIONS: This meta-analysis shows that among selected STEMI patients undergoing primary angioplasty, SES as compared to BMS is safe and associated with a significant reduction in TVR at 1 and 2-3 years follow-up.
BACKGROUND: Recent concerns have emerged on the potential higher risk of stent thrombosis after DES implantation, that might be even more pronounced among STEMI patients. The aim of the current study was to perform a meta-analysis to evaluate the benefits and safety of Sirolimus-Eluting Stent (SES) as compared to BMS in patients undergoing primary angioplasty for STEMI. METHODS: The literature was scanned by formal searches of electronic databases (MEDLINE and CENTRAL). We examined all completed randomized trials of DES for STEMI. The following keywords were used for study selection: randomized trial, myocardial infarction, reperfusion, primary angioplasty, stenting, DES, sirolimus-eluting stent (SES), Cypher. Information on study design, type of stent, inclusion and exclusion criteria, primary endpoint, number of patients, angiographic and clinical outcome, were extracted by two investigators. Disagreements were resolved by consensus. RESULTS: A total of 9 trials were included in the meta-analysis, involving 2,769 patients (1389 or 50.2% randomized to DES and 1,380 or 49.8% randomized to BMS). At 12 months follow-up, SES was associated with a significant reduction in TVR (4.9% vs. 13.6%, p < 0.0001), with a trend in benefits in mortality (2.9% vs. 4.2%, p = 0.08) and reinfarction (3.0% vs. 4.3%, p = 0.06), without any significant difference in stent thrombosis (1.9% vs. 2.5%, p = 0.36). Safety and efficacy of DES were confirmed at 2-3 years follow-up (data available from 4 trials including 569 patients). CONCLUSIONS: This meta-analysis shows that among selected STEMI patients undergoing primary angioplasty, SES as compared to BMS is safe and associated with a significant reduction in TVR at 1 and 2-3 years follow-up.
Authors: Christian Spaulding; Patrick Henry; Emmanuel Teiger; Kevin Beatt; Ezio Bramucci; Didier Carrié; Michel S Slama; Bela Merkely; Andrejs Erglis; Massimo Margheri; Olivier Varenne; Ana Cebrian; Hans-Peter Stoll; David B Snead; Christoph Bode Journal: N Engl J Med Date: 2006-09-14 Impact factor: 91.245
Authors: Gerrit J Laarman; Maarten J Suttorp; Maurits T Dirksen; Loek van Heerebeek; Ferdinand Kiemeneij; Ton Slagboom; L Ron van der Wieken; Jan G P Tijssen; Benno J Rensing; Mark Patterson Journal: N Engl J Med Date: 2006-09-14 Impact factor: 91.245
Authors: Bo Lagerqvist; Stefan K James; Ulf Stenestrand; Johan Lindbäck; Tage Nilsson; Lars Wallentin Journal: N Engl J Med Date: 2007-02-12 Impact factor: 91.245
Authors: Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell Journal: N Engl J Med Date: 2004-01-15 Impact factor: 91.245
Authors: Kevin R Bainey; Colleen M Norris; Michelle M Graham; William A Ghali; Merril L Knudtson; Robert C Welsh Journal: Int J Cardiol Date: 2007-08-08 Impact factor: 4.164
Authors: Bas L van der Hoeven; Su-San Liem; J Wouter Jukema; Navin Suraphakdee; Hein Putter; Jouke Dijkstra; Douwe E Atsma; Marianne Bootsma; Katja Zeppenfeld; Pranobe V Oemrawsingh; Ernst E van der Wall; Martin J Schalij Journal: J Am Coll Cardiol Date: 2008-02-12 Impact factor: 24.094
Authors: Eliano Pio Navarese; Stefano De Servi; Antonino Buffon; Harry Suryapranata; Giuseppe De Luca Journal: J Thromb Thrombolysis Date: 2011-02 Impact factor: 2.300
Authors: Giuseppe De Luca; Maurits T Dirksen; Christian Spaulding; Henning Kelbæk; Martin Schalij; Leif Thuesen; Bas van der Hoeven; Marteen A Vink; Christoph Kaiser; Carmine Musto; Tania Chechi; Gaia Spaziani; Luis Salvador Diaz de la Llera; Vincenzo Pasceri; Emilio Di Lorenzo; Roberto Violini; Harry Suryapranata; Gregg W Stone Journal: Clin Res Cardiol Date: 2014-04-01 Impact factor: 5.460
Authors: Giuseppe De Luca; Jeffrey Wirianta; Jae-Hwan Lee; Christoph Kaiser; Emilio Di Lorenzo; Harry Suryapranata Journal: J Thromb Thrombolysis Date: 2014-10 Impact factor: 2.300
Authors: Giuseppe De Luca; Maurits T Dirksen; Henning Kelbæk; Leif Thuesen; Marteen A Vink; Christoph Kaiser; Tania Chechi; Gaia Spaziani; Emilio Di Lorenzo; Harry Suryapranata; Gregg W Stone Journal: J Thromb Thrombolysis Date: 2015-01 Impact factor: 2.300